Imagine using artificial intelligence to compare two seemingly unrelated creations—biological tissue and Beethoven's ...

Nucleai, an AI-powered spatial biology company, will present two abstracts at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. The presentations will detail how Nucleai's AI-driven ...

The Rocky Mountain Community Science Conference (RMCSC), hosted by the University of Wyoming’s Biodiversity Institute in collaboration with Audubon Rockies, will take place Thursday, Dec. 5, from 9 a.

In Taipei, Nvidia gave us a peek at some of the latest software implementations of AI (most of them, predictably, assisted by the company's discrete graphics engines) that will dazzle gamers ...

Design studio Spread has produced a series of colourful covers with geometric designs for Japan's Journal of Architecture and ...

Open 3D Engine (O3DE) is an Apache 2.0-licensed multi-platform 3D engine that enables developers and content creators to build AAA games, cinema-quality 3D worlds, and high-fidelity simulations ...

Create diverse, relevant, ethical and socially-aware brands for clients, corporations, communities and cultures. MA Graphic Branding and Identity will help you go beyond visual identity, typographical ...

In perhaps the most widely repeated story in all of science, Newton is said to have chanced upon the theory of gravity while contemplating under the shade of an apple tree. According to the legend ...

NASA announced two awards Thursday to establish scientific consortia – multi-institutional coalitions to conduct ground-based studies that help address the agency’s goals of maintaining a sustained ...

FLOP-olis.” The latest film from Francis Ford Coppola is a blatant sign of the cinema legend’s declining prowess. Coppola’s ...

Non-fiction publishing is failing its readers. It is pumping out books with supposedly game-changing ideas, without bothering to ensure basic accuracy. These tomes have the appearance of academic ...

Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing ...